J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure

Key Takeaways J&J is discontinuing Imaavy's RA development after phase IIa results showed no added benefit.The DAISY study tested Imaavy plus anti-TNF aplha in refractory RA but did not improve outcomes.J&J still projects Imaavy as a $5B+ sales driver, with trials ongoing in multiple immune disorders.Johnson & Johnson (JNJ) announced that it is discontinuing the development of an investigational combination therapy involving Imaavy (nipocalimab) in the rheumatoid arthritis (RA) indication.This decision is b ...